Novo Holdings A/S
In its 13F for Q2 2026 (holdings as of June 30, 2026, filed August 14, 2026), Novo Holdings A/S reported 25 stock positions worth $1.7 billion. Its top holding was Edgewise Therapeutics (EWTX) at 12.6% of the portfolio, followed by ASML Holding NV-NY Reg SHS (ASML, 11.0%) and Hemab Therapeutics (COAG, 8.9%). Compared with Q1 2026, it opened 6 new positions, sold out of 3, added to 2 and reduced 8. The biggest buy was a new position in Hemab Therapeutics (COAG) and the biggest sale an exit from Apogee Therapeutics (APGE).
- Most Recent 13F
- Q2 2026
- Location
- HELLERUP, G7
- CIK
- 0001388325
- Portfolio Value
- $1.7B (Q2 2026)
- SEC Filing
- 0001388325-26-000042 ↗ filed Aug 14, 2026
Holdings Value
Holdings 25 stocks · $1.7B
| EWTX Edgewise Therapeutics Inc. | 12.62% | 5,350,000 | $217.4M | No change |
| ASML ASML Holding NV-NY Reg SHS filed as ASML HLDG NV | 10.97% | 94,946 | $188.9M | No change |
| COAG Hemab Therapeutics Holdings | 8.92% | 4,180,550 | $153.6M | New |
| BN Brookfield Corp. | 8.68% | 3,496,245 | $149.5M | No change |
| MPLT Maplight Therapeutics Inc. | 7.67% | 3,686,622 | $132.1M | No change |
| MIRM Mirum Pharmaceuticals Inc. | 7.65% | 1,125,000 | $131.7M | Reduce -15.1% |
| AVLN Avalyn Pharma Inc. | 7.42% | 3,883,289 | $127.8M | New |
| CRM Salesforce Inc. | 3.58% | 393,187 | $61.6M | No change |
| AVBP Arrivent Biopharma Inc. | 3.03% | 1,500,000 | $52.1M | Reduce -22.8% |
| ELVN Enliven Therapeutics Inc. | 2.95% | 1,000,000 | $50.8M | Reduce -21.9% |
| CRNX Crinetics Pharmaceuticals Inc. | 2.87% | 1,320,000 | $49.4M | Reduce -14.8% |
| PHVS Pharvaris NV | 2.81% | 1,400,000 | $48.4M | Reduce -20.0% |
| FND Floor & Decor Holdings Inc. Class A | 2.75% | 797,000 | $47.3M | New |
| PCVX Vaxcyte Inc. | 2.70% | 800,000 | $46.5M | Reduce -7.0% |
| FDMT 4D Molecular Therapeutics Inc. | 2.51% | 3,249,178 | $43.2M | Reduce -11.0% |
| VRDN Viridian Therapeutics Inc. | 2.28% | 2,135,000 | $39.2M | Add +6.8% |
| CLDX Celldex Therapeutics Inc. | 2.21% | 1,025,000 | $38.1M | Reduce -14.6% |
| ALMS Alumis Inc. | 1.80% | 1,100,000 | $31.0M | New |
| XENE Xenon Pharmaceuticals Inc. | 1.70% | 485,438 | $29.3M | No change |
| BABA Alibaba Group Holding-SP ADR | 1.43% | 257,327 | $24.7M | No change |
| DYN Dyne Therapeutics Inc. | 1.24% | 960,394 | $21.3M | New |
| BBOT Bridgebio Oncology Therapeut | 1.00% | 2,250,000 | $17.1M | Add +2.9% |
| INSM Insmed Inc. | 0.75% | 120,723 | $12.9M | New |
| MQ Marqeta Inc. | 0.42% | 441,558 | $7.2M | No change |
| LNZA Lanzatech Global Inc. | 0.06% | 158,148 | $1.1M | No change |
Portfolio Sells Q1 2026 → Q2 2026
| APGE Apogee Therapeutics Inc. | Sold out | 0.00% | −3.07 |
| BMRN Biomarin Pharmaceutical Inc. | Sold out | 0.00% | −3.02 |
| MIRM Mirum Pharmaceuticals Inc. | Reduce -15.1% | 7.65% | −2.27 |
| CRNX Crinetics Pharmaceuticals Inc. | Reduce -14.8% | 2.87% | −1.69 |
| PCVX Vaxcyte Inc. | Reduce -7.0% | 2.70% | −1.35 |
| PHVS Pharvaris NV | Reduce -20.0% | 2.81% | −1.19 |
| ELVN Enliven Therapeutics Inc. | Reduce -21.9% | 2.95% | −1.12 |
| CLDX Celldex Therapeutics Inc. | Reduce -14.6% | 2.21% | −0.87 |
| AVBP Arrivent Biopharma Inc. | Reduce -22.8% | 3.03% | −0.60 |
| VALN Valneva SE - ADR | Sold out | 0.00% | −0.54 |
| FDMT 4D Molecular Therapeutics Inc. | Reduce -11.0% | 2.51% | −0.24 |
Portfolio Buys Q1 2026 → Q2 2026
| COAG Hemab Therapeutics Holdings | New | 8.92% | +8.92 |
| AVLN Avalyn Pharma Inc. | New | 7.42% | +7.42 |
| FND Floor & Decor Holdings Inc. Class A | New | 2.75% | +2.75 |
| ALMS Alumis Inc. | New | 1.80% | +1.80 |
| DYN Dyne Therapeutics Inc. | New | 1.24% | +1.24 |
| INSM Insmed Inc. | New | 0.75% | +0.75 |
| BBOT Bridgebio Oncology Therapeut | Add +2.9% | 1.00% | −0.59 |
| VRDN Viridian Therapeutics Inc. | Add +6.8% | 2.28% | −0.89 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 25 | $1.7B | EWTX, ASML, COAG, BN, MPLT |
| Q1 2026 | 22 | $1.2B | EWTX, BN, ASML, MIRM, MPLT |
| Q4 2025 | 24 | $1.3B | BN, EWTX, ASML, MIRM, CRM |
| Q3 2025 | 27 | $1.6B | VTI, BN, ASML, MIRM, EWTX |
| Q2 2025 | 29 | $1.4B | VTI, BN, ASML, CRM, MIRM |
| Q1 2025 | 31 | $1.3B | VTI, BN, EWTX, ASML, CRM |
| Q4 2024 | 34 | $1.7B | VTI, BN, TEM, EWTX, ASML |
| Q3 2024 | 37 | $2.0B | VTI, TEM, BN, EWTX, CORT |
| Q2 2024Amended | 38 | $1.9B | VTI, BN, TEM, ASML, CRM |
| Q1 2024 | 35 | $1.4B | ASML, BN, CRM, EPC, CORT |